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How to treat recurrences after
Avastin treatment for
neovascular AMD: stick to
Avastin or switch to Lucentis?
Before the recent approvement of ranibizu-
mab (Lucentis) for the treatment of neovas-
cular age-related macular degeneration
(AMD), bevazicumab (Avastin) had been
successfully used as an off-label treatment
for this condition.1 As a consequence, in
daily practice we are confronted with a large
number of patients having received Avastin
injections in the past, now facing a recur-
rence of the disease and therefore requiring
additional injections.2 This leaves the
ophthalmologist in a medical dilemma:
should one continue with the off-label drug
Avastin or switch to Lucentis? From a
clinical point of view and disregarding the
legal aspects of continuing an off label
treatment, this is not easy to answer, as
there are no comparative data available at
present.3 Given this background, we com-
pared the effect of Lucentis and Avastin in a
retrospective analysis of a matched case
series of patients with recurrent neovascular
AMD who were initially treated with
Avastin.
Sixty-four patients who had finished
upload therapy were selected. Upload ther-
apy existed of consecutive injections of
intravitreal Avastin every 4–6-week untill
the disapearance of macular oedema on
OCT. All of these patients presented with
a recurrence of neovascular AMD and had
undergone treatment of the recurrence with
Avastin (group 1, n = 32) or Lucentis (group
2, n = 32) thereafter. Comparing both
groups, there was no significant difference
concerning visual acuity (VA), central macu-
lar oedema in OCT measurement and age
before therapy; this also went for the gain of
VA and decrease in macular oedema follow-
ing upload therapy, as well as the documen-
ted decrease in VA and increase in retinal
thickness measured as a result of the
recurrence of the disease, indicating that
both groups were very well matched
(table 1). In both groups, therapy for the
recurrence continued until a resolution of
the macular oedema with sequential injec-
tions at 4–6-week intervals was seen, num-
ber of injections did not differ significantly
(group 1: 2.5 injections, group 2: 2.7 injec-
tions). Comparing patients having received
Lucentis and Avastin, no significant differ-
ence concerning the development of VA (see
fig 1) was seen, with both groups experien-
cing an improvement of VA. In contrast,
concerning the regression of macular
oedema, the effect was more pronounced
in group 2 (p,0.028).
However, using Lucentis or Avastin, the
mean VA did not reach the level measured
before the recurrence had occurred (p,0.05,
Wilcoxon test for paired samples).
Our results indicate a difference in the
effect of Lucentis and Avastin when used for
the treatment of a recurrence of neovascular
AMD after initial Avastin treatment, with
slightly better results seen for Lucentis (at
Table 1 Histological profile of the cases reviewed
All
cases Fatal outcome group Surviving group
x2 p ValueN = 19 N = 6 % N = 13 %
Degree of differentiation
Well differentiated 6 0 0.0 6 100.0 4.05 0.10
Moderately differentiated 4 1 25.0 3 75.0 0.10 1.0
Poorly differentiated 9 5 55.5 4 44.5 4.55 0.057*
Presence and type of rosette
Flexner Wintersteiner 8 2 25.0 6 75.0 0.28 1.0
Homer Wright 2 0 0 2 100 1.0 1.0
Perivascular 8 6 75.0 2 25.0 12.06 0.001*
Degenerative changes
Necrosis 14 6 42.9 8 57.1 3.13 0.12
Calcification 1 0 0 1 100 1.0 1.0
Optic nerve involvement
Postlaminar 11 6 54.5 5 45.5 6.38 0.018*
Prelaminar 8 0 0 8 100 3.25 0.136
p Value = two-tailed p value.
*All cases with fatal outcomes had perivascular tumour cuffing, which when compared with the two cases among the surviving group with
perivascular tumour cuffing was statistically significant (p = 0.001, x2 = 12.06).
All cases with fatal outcomes exhibited significant tumour necrosis compared with the eight among the surviving group (p = 0.12;
x2 = 3.13).
Figure 1 Treatment of recurrent neovascular
age-related macular degeneration after
intravitreal Avastin intravitreal therapy. Both
groups showed an increase in visual acuity (VA)
and a decrease in macular oedema. However,
regarding the regression of macular oedema in
our groups, there was more benefit for patients
having been treated with Lucentis (p,0.028)
ETDRS, Early Treatment Diabetic Retinopathy
Study; OCT, optical coherence tomography.
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least concerning the regression of macular
oedema). We are of course aware that
definite conclusions cannot be drawn, and
recommendations can not be given based
on our data due to the small number of
patients and the retrospective nature of our
analysis. Nevertheless, as both groups were
carefully matched as mentioned above, our
results underline the need for a prospective
comparative trial as mentioned by other
groups.3
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Table 1 Characteristics of the two groups
Group 1—Rescue treatment:
Avastin Group 2—Rescue treatment: Lucentis p Value
Baseline
Age (years) 76.9 77.2 0.54
Sex (female) 75% 69% 0.32
VA (before upload) 0.3 0.27 0.99
Macular oedema (OCT) 332 mm 338 mm 0.5
Upload with Avastin
Pretreatment (no. of Avastin injections during upload) 3 2.7 0.31
OCT—after upload 242 mm 221 mm 0.2
VA increase during upload (ETDRS letters) +5.9 +8.7 0.4
Recurrence
Recurrence (weeks after last injection) 17.8 14.6 0.3
Recurrence (ETDRS letters) 211.3 211.9 0.6
Recurrence (OCT) +82 mm +98 mm 0.5
In the mean, there was no difference between the groups before treatment of recurring neovascular AMD. This went for baseline characteristics before upload therapy, effects on visual acuity
(VA) and retinal thickness during upload treatment and clinical parameters when presenting with the recurrence of neovascular AMD.
ETDRS, Early Treatment Diabetic Retinopathy Study; OCT, optical coherence tomography.
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